Full text is available at the source.
Abstract
More than 2.5 billion adults worldwide are affected by obesity and type 2 diabetes mellitus (T2DM).
- Unimolecular polypharmacology designs single molecules to target multiple receptors or pathways.
- Tirzepatide and retatrutide have shown superior efficacy in managing obesity and T2DM compared to traditional single agonists.
- Tirzepatide has been noted for its effectiveness in weight loss and glycemic control, along with additional cardiovascular and renal benefits.
- Challenges with these therapies include gastrointestinal side effects, patient compliance issues, and weight rebound after treatment cessation.
- The development of these agents highlights the potential of unimolecular polypharmacology in treating metabolic diseases.
Simplified